Clinical role of brexpiprazole in depression and schizophrenia
Nishant B Parikh, Diana M Robinson, Anita H Clayton Psychiatry and Neurobehavioral Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA Abstract: Brexpiprazole, a serotonin–dopamine activity modulator, is the second D2 partial agonist to come to market and has be...
Main Authors: | Parikh NB, Robinson DM, Clayton AH |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2017-03-01
|
Series: | Therapeutics and Clinical Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-role-of-brexpiprazole-in-depression-and-schizophrenia-peer-reviewed-article-TCRM |
Similar Items
-
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
by: Bruijnzeel D, et al.
Published: (2016-05-01) -
Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
by: Yuichi Inoue, et al.
Published: (2021-05-01) -
Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA
by: Aigbogun MS, et al.
Published: (2018-08-01) -
Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials
by: Kishi T, et al.
Published: (2018-10-01) -
Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
by: Inada K, et al.
Published: (2020-10-01)